Orgenesis Inc.·Healthcare

Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company's lead ophthalmic program and establishing a foundation for expansion into additional antiviral indications. The acquisition expands the company's development pipeline beyond ocular infections into a set of focused therapeutic areas: eyecare, systemic infectious disease, dermatology and medical countermeasures for high-consequence pathogens such as filoviruses, which form the core pillars of Okogen's Ranpirnase Platform.

Orgenesis (NASDAQ: ORGS - Get Free Report) and UCB (OTCMKTS:UCBJF - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Insider and Institutional Ownership 22.6% of Orgenesis shares are held

Orgenesis Inc. (NASDAQ: ORGS - Get Free Report) shares rose 300% during mid-day trading on Thursday. The stock traded as high as $0.60 and last traded at $0.60. Approximately 100 shares traded hands during trading, a decline of 84% from the average daily volume of 636 shares. The stock had previously closed at $0.15. Orgenesis
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Healthcare
Biotechnology
146
2012-03-13
3.81